Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: Potent, orally-active 1,4-disubstituted imidazoles
作者:Robert L. Dow、John R. Hadcock、Dennis O. Scott、Steven R. Schneider、Ernest S. Paight、Philip A. Iredale、Philip A. Carpino、David A. Griffith、Marlys Hammond、Paul DaSilva-Jardine
DOI:10.1016/j.bmcl.2009.07.130
日期:2009.9
A new series of CB(1) receptor antagonists incorporating an imidazole-based isosteric replacement for the hydrazide moiety of rimonabant (SR141716) is disclosed. Members of this imidazole series possess potent/selective binding to the rCB(1) receptor and exhibit potent hCB(1) functional activity. Isopropyl analog 9a demonstrated activity in the tetrad assay and was orally-active in a food intake model. (C) 2009 Published by Elsevier Ltd.
CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
申请人:Pfizer Products Inc.
公开号:EP1556373A1
公开(公告)日:2005-07-27
US9662320B2
申请人:——
公开号:US9662320B2
公开(公告)日:2017-05-30
[EN] CANNABINOID RECEPTOR LIGANDS AND USES THEREOF<br/>[FR] LIGANDS DES RECEPTEURS DES CANNABINOIDES ET APPLICATIONS DE CEUX-CI
申请人:PFIZER PROD INC
公开号:WO2004035566A1
公开(公告)日:2004-04-29
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the modulation of the cannabinoid receptors in animals are described herein.
Cannabinoid receptor ligands and uses thereof
申请人:Pfizer Inc.
公开号:US20040077650A1
公开(公告)日:2004-04-22
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the modulation of the cannabinoid receptors in animals are described herein.
1